Related Experiment Videos
Lorcainide -- an anti-arrhythmic agent for ventricular arrhythmias
Insights
Lorcainide effectively reduced ventricular ectopic beats in post-myocardial infarction patients. Long-term use improved anti-arrhythmic response, with side effects like insomnia diminishing over time.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Post-myocardial infarction patients are at risk for ventricular arrhythmias.
- Effective long-term anti-arrhythmic therapy is crucial for managing this patient population.
Purpose of the Study:
- To evaluate the long-term anti-arrhythmic efficacy and safety of lorcainide.
- To assess the drug's impact on ventricular ectopic activity in post-MI patients.
Main Methods:
- A study involving 20 ambulatory patients post-myocardial infarction.
- Long-term administration of lorcainide with regular monitoring of ventricular ectopic beats.
- Electrocardiographic assessments to evaluate cardiac effects.
Main Results:
- Lorcainide significantly reduced ventricular ectopic beats in a majority of patients (over 70% reduction in 17/20, over 90% in 11/20).
- Anti-arrhythmic response improved with sustained drug administration.
- Transient insomnia was the most common side effect, decreasing over time.
Conclusions:
- Lorcainide demonstrates useful long-term anti-arrhythmic efficacy against ventricular ectopic activity.
- The drug is a valuable addition to the therapeutic options for managing post-myocardial infarction arrhythmias.
Abstract:
The long-term anti-arrhythmic efficacy of lorcainide (R15 889) was studied in 20 ambulatory postmyocardial infarction patients. Lorcainide reduced the frequency of ventricular ectopic beats by more than 70% and 90% in 17 and 11 of the patients respectively. The anti-arrhythmic response improved with long-term administration of the drug. Fourteen patients complained of insomnia during the early stages of the study, but this side-effect waned later on. On electrocardiographic examination, the P-R interval, QTc interval and QRS duration were prolonged, and T-wave changes were noted while the patients were receiving lorcainide. Lorcainide seems to be a useful addition to the available anti-arrhythmic agents, and should form part of the armamentarium against ventricular ectopic activity.